The study involved more than 800 patients who have weight-related comorbidities not related to Type 2 diabetes. For 12 weeks, the participants engaged in an “intensive lifestyle intervention” that included a low-calorie diet, exercise and frequent counseling sessions, Eli Lilly said in an Oct. 15 news release.
About 580 people lost at least 5% of their weight after the 12 weeks, and among that cohort, they were split between taking Mounjaro or a placebo. After 84 weeks, participants who took Mounjaro lost, on average, 26.6% of their weight — equal to 64.4 pounds each. The placebo group achieved a 3.8% weight loss, or nine pounds. Eli Lilly said the results show Mounjaro’s “superiority” over a placebo.
The most common side effects were “gastrointestinal-related and generally mild to moderate in severity,” the drugmaker said.
The therapy is a glucagon-like peptide-1 receptor agonist, which is the same medication class as two popular Novo Nordisk medications: Type 2 diabetes drug Ozempic and weight loss therapy Wegovy.
The FDA and European Medicines Agency are currently evaluating whether to approve Mounjaro as a weight loss drug.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
